Thursday, July 10, 2014
supercalifragilisticexpialidocious or superovulationcwdtsepriondocious
?
Superovulation and embryo recovery in Red deer (Cervus elaphus ) hinds.
Fennessy PF1, Fisher MW, Shackell GH, Mackintosh CG. Author information
1Invermay Agricultural Centre Private Bag Mosgiel New Zealand.
Abstract
In two experiments, Red deer hinds were synchronized with intravaginal
progesterone and were given 4 d of treatment (3 d before progesterone withdrawal
and 1 d after) with an ovine follicle stimulating hormone (FSH) preparation
which had a claimed low level of luteinizing hormone (LH) contamination. In
Experiment 1, 12 hinds received one of four FSH levels by osmotic minipump.
Hinds were run with fertile stags, and laparotomy and embryo recovery were
performed 9 d after progesterone withdrawal. The ovulation rates (mean of three
hinds per dosage) were 1.0, 2.0, 4.3 and 15.3 (number of corpora lutea counted)
for estimated daily dosages rates of 0.036, 0.071, 0.11 and 0.14 units FSH
preparation/day; the response to the increasing dosage was exponential
(P<0 .01="" 0.14="" 11.0="" 18="" 1="" 2="" 3.0="" 34="" 38="" 47="" 63="" 72="" a="" all="" an="" and="" be="" being="" better="" both="" breeding="" by="" considered="" day="" deer="" difference="" div="" eight="" either="" estrus="" experiment="" fertilized="" flushing="" for="" fsh="" function="" higher="" hinds="" improved="" in="" injection.="" intramuscular="" later="" mean="" minipump="" of="" on="" only="" or="" ova="" overall="" ovulation="" p="" performed="" perhaps="" preparation="" previously="" profile="" progesterone="" quality.="" rate="" rates="" received="" recorded="" recovered="" recovery="" red="" respectively="" results="" season="" significant="" significantly="" synchronization.="" than="" that="" the="" those="" to="" transferable="" units="" used="" was="" were="" with="">
>> ovine follicle stimulating hormone (FSH)
F8174 Sigma Follicle Stimulating Hormone from sheep pituitary Synonym: FSH
Louping-ill vaccine sheep scrapie blunder
Vaccine for issue had to be free from detectable, living virus and capable
of protecting sheep against a test dose of virus applied subcutaneously. The
1935 vaccine conformed to these standards and was issued for inoculation in
March as three separate batches labelled 1, 2, and 3. The tissues of 140 sheep
were employed to make batch 1 of which 22,270 doses were used; 114 to make batch
2 of which 18,000 doses were used and 44 to make batch 3 of which 4,360 doses
were used. All the sheep tissues incorporated in the vaccine were obtained from
yearling sheep. During 1935 and 1936 the vaccine proved highly efficient in the
prevention of loup-ill and no user observed an ill-effect in the inoculated
animals. In September, 1937, two and a half years after vaccinating the sheep,
two owners complained that scrapie, a disease which had not before been observed
in the Blackface breed, was appearing in their stock of Blackface sheep and
further that it was confined to animals vaccinated with louping-ill vaccine in
1935. At that stage it was difficult to conceive that the occurrence could be
associated with the injection of the vaccine but in view of the implications, I
visited most of the farms on which sheep had been vaccinated in 1935. It was at
this point that the investigation reached its dramatic phase; I shall not forget
the profound effect on my emotions when I visited these farms and was warmly
welcomed because of the great benefits resulting from the application of
louping-ill vaccine, wheras the chief purpose of my visit was to determine if
scrapie was appearing in the inoculated sheep. The enquiry made the position
clear. Scrapie was developing in the sheep vaccinated in 1935 and it was only in
a few instances that the owner was associating the occurrence with louping-ill
vaccination. The disease was affecting all breeds and it was confined to the
animals vaccinated with batch 2. This was clearly demonstrated on a number of
farms on which batch 1 had been used to inoculate the hoggs in 1935 and batch 2
to inoculate the ewes. None of the hoggs, which at this time were three-
year-old ewes. At this time it was difficult to forecast whether all of the
18,000 sheep which had received batch 2 vaccine would develop scrapie. It was
fortunate, however, that the majority of the sheep vaccinated with batch 2 were
ewes and therfore all that were four years old and upwards at the time of
vaccination had already been disposed of and there only remained the ewes which
had been two to three years old at the time of vaccination, consequently no
accurate assessment of the incidence of scrapie could be made. On a few farms,
however, where vaccination was confined to hoggs, the incidence ranged from 1
percent, to 35 percent, with an average of about 5 percent. Since batch 2
vaccine had been incriminated as a probable source of scrapie infection, an
attempt was made to trace the origin of the 112 sheep whose tissues had been
included in the vaccine. It was found that they had been supplied by three
owners and that all were of the Blackface or Greyface breed with the exception
of eight which were Cheviot lambs born in 1935 from ewes which had been in
contact with scrapie infection. Some of these contact ewes developed scrapie in
1936-37 and three surviving fellow lambs to the eight included in the batch 2
vaccine of 1935 developed scrapie, one in September, 1936, one in February,
1937, and one in November, 1937. There was, therefore, strong presumptive
evidence that the eight Cheviot lambs included in the vaccine althought
apparently healthy were, in fact, in the incubative stage of a scrapie infection
and that in their tissues there was an infective agent which had contaminated
the batch 2 vaccine, rendering it liable to set up scrapie. If that assumption
was correct then the evidence indicated that:-
(1) the infective agent of scrapie was present in the brain, spinal cord
and or spleen of infected sheep: (2) it could withstand a concentration of
formalin of 0-35 percent, which inactivated the virus of louping-ill: (3) it
could be transmitted by subcutaneous inoculation; (4) it had an incubative
period of two years and longer.
see part of old report I received;
see vaccines;
(It was noted with concern that hormone extracts could be manufactured by a
veterinary surgeon for administration to animals under his care without any
Medicines Act Control.)
PITUITARY EXTRACT
This was used to help cows super ovulate.
*** This tissue was considered to be of greatest risk of containing BSE and
consequently transmitting the disease. ***
BEEF BRAIN AND BRAIN INFUSION BROTHS
Considered to be of great risk.
NON-LICENSED HUMAN TISSUE DEVICES WERE NOT COMMERCIALLY AVAILABLE
snip...
I was quite prepared to believe in unofficial pituitary hormones, also in
the 1970's, whether as described by Dr. Little, or in other circumstances, for
animal use.
snip...
The fact that there were jars of pituitaries (or extract) around on shelves
is attested by the still potent 1943 pituitaries, described in Stockell Hartree
et al. (J/RF/17/291) which had come from the lab. at Mill Hill. Having taken the
trouble to collect them, they were not lightly thrown out...
B.S.E. and Veterinary Medicines
Thank you very much indeed for your letter of the 26th of January outlining
to me the various steps that are proposing to take in order to reduce the risk
from B.S.E. in veterinary medicines. It is, as you say, and extremely difficult
problem. ....
http://web.archive.org/web/20030526124448/http://www.bseinquiry.gov.uk/files/yb/1989/01/30008001.pdf
Draft cover letter to product licence holders (considered by Human and Vet
Medicines including deer)
COMMERCIAL IN CONFIDENCE
MEDICINES ACT - VETERINARY PRODUCTS COMMITTEE
5 BLANK PAGES. ...TSS
7. Any Other Business
TWA LITTLE STATEMENT 331
8 June 1988 Internal CVL meeting to discuss the implications of BSE to
Biologicals Products containing bovine extracted material (Annex 6). (YB
88/06.08/11.1-11.2) Following a detailed review of situation the following
recommendations were made:
1. Specific concern over use of pituitary gland products by veterinary
surgeons and companies. Paper to be produced for Tolworth (Veterinary Medicines
Division).
2. Urgent review of all products both immunological and pharmaceutical for
possible inclusion of ingredients of bovine origin.
3. Draft guidelines to be presented in full to the National Office of
Animal Health (NOAH), the trade body representing the Veterinary Medicines part
of the pharmaceutical industry, at next meeting on 11 July 1988
TWA LITTLE minute
2. We have identified one problem over where we are unable to act and this
is the use of gonadotrophins in embryo transfer work. Some veterinary surgeons
are quite legally using this exemption from the Medicines Act contained in
Section 9(2) to prepare gonadotrophins from pituitary glands from various
species, including cattle. These hormones are used to stimulate superovulation
in donor cows.
COMMERCIAL IN CONFIDENCE
3.2 Minute 5.3 - 5.4 Bovine Spongiform Encephalopathy
It was reported that some replies had been received from Companies using
pituitary glands in their products. Copies of the BSE document had also been
sent to DHSS and NIBSC.
and then another 3 + pages of blank space. ...TSS
COMMERCIAL IN CONFIDENCE
BSE - CURRENT POSITION WITH VETERINARY LICENCED PRODUCTS (MA.1968)
There are three areas of particular concern, vaccines (including emergency
vaccines), pharmaceuticals which are covered by MA licences and unlicenses
hormonal products produced under exemptions claimed under (Section 9(2)
Medicines Act).
1) Vaccines
NOT FOR PUBLICATION
another 6 pages of blank space. ...TSS
COMMERCIAL IN CONFIDENCE
COMMERCIAL IN CONFIDENCE
Medicines Act - Veterinary Products Committee
COMMERCIAL IN CONFIDENCE
MANAGEMENT IN CONFIDENCE
CERTIFIED BSE-FREE HERDS FOR SOURCE OF MATERIAL FOR BIOLOGICAL
PRODUCTS
Subject: BSE--U.S. 50 STATE CONFERENCE CALL Jan. 9, 2001 Date: Tue, 9 Jan
2001 16:49:00 -0800 From: "Terry S. Singeltary Sr." Reply-To: Bovine Spongiform
Encephalopathy To: BSE-L@uni-karlsruhe.de
[host Richard Barns] and now a question from Terry S. Singeltary of CJD
Watch.
[TSS] yes, thank you, U.S. cattle, what kind of guarantee can you give for
serum or tissue donor herds?
[no answer, you could hear in the back ground, mumbling and 'we can't. have
him ask the question again.]
[host Richard] could you repeat the question?
[TSS] U.S. cattle, what kind of guarantee can you give for serum or tissue
donor herds?
[not sure whom ask this] what group are you with?
[TSS] CJD Watch, my Mom died from hvCJD and we are tracking CJD
world-wide.
[not sure who is speaking] could you please disconnect Mr. Singeltary
[TSS] you are not going to answer my question?
[not sure whom speaking] NO
from this point, i was still connected, got to listen and tape the whole
conference. at one point someone came on, a woman, and ask again;
[unknown woman] what group are you with?
[TSS] CJD Watch and my Mom died from hvCJD we are trying to tract down CJD
and other human TSE's world wide. i was invited to sit in on this from someone
inside the USDA/APHIS and that is why i am here. do you intend on banning me
from this conference now?
at this point the conference was turned back up, and i got to finish
listening. They never answered or even addressed my one question, or even
addressed the issue. BUT, i will try and give you a run-down for now, of the
conference.
snip...full text ;
2012
PO-039: A comparison of scrapie and chronic wasting disease in white-tailed
deer
Justin Greenlee, Jodi Smith, Eric Nicholson US Dept. Agriculture;
Agricultural Research Service, National Animal Disease Center; Ames, IA USA
snip...
The results of this study suggest that there are many similarities in the
manifestation of CWD and scrapie in WTD after IC inoculation including early and
widespread presence of PrPSc in lymphoid tissues, clinical signs of depression
and weight loss progressing to wasting, and an incubation time of 21-23 months.
Moreover, western blots (WB) done on brain material from the obex region have a
molecular profile similar to CWD and distinct from tissues of the cerebrum or
the scrapie inoculum. However, results of microscopic and IHC examination
indicate that there are differences between the lesions expected in CWD and
those that occur in deer with scrapie: amyloid plaques were not noted in any
sections of brain examined from these deer and the pattern of immunoreactivity
by IHC was diffuse rather than plaque-like.
*** After a natural route of exposure, 100% of WTD were susceptible to
scrapie.
Deer developed clinical signs of wasting and mental depression and were
necropsied from 28 to 33 months PI. Tissues from these deer were positive for
PrPSc by IHC and WB. Similar to IC inoculated deer, samples from these deer
exhibited two different molecular profiles: samples from obex resembled CWD
whereas those from cerebrum were similar to the original scrapie inoculum. On
further examination by WB using a panel of antibodies, the tissues from deer
with scrapie exhibit properties differing from tissues either from sheep with
scrapie or WTD with CWD. Samples from WTD with CWD or sheep with scrapie are
strongly immunoreactive when probed with mAb P4, however, samples from WTD with
scrapie are only weakly immunoreactive. In contrast, when probed with mAb’s 6H4
or SAF 84, samples from sheep with scrapie and WTD with CWD are weakly
immunoreactive and samples from WTD with scrapie are strongly positive. This
work demonstrates that WTD are highly susceptible to sheep scrapie, but on first
passage, scrapie in WTD is differentiable from CWD.
2011
*** After a natural route of exposure, 100% of white-tailed deer were
susceptible to scrapie.
kind regards, terry
0>
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home